The role of chemotherapy in the treatment of central neurocytoma

AIM: Central neurocytoma (CN) is a rare WHO grade II central nervous system (CNS) tumor. This is an update on chemotherapeutic agents used in its treatment. PATIENTS & METHODS: An institutional review board-approved, chart review of patients seen at our institution resulted in a single case trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnson, Margaret O, Kirkpatrick, John P, Patel, Mallika P, Desjardins, Annick, Randazzo, Dina M, Friedman, Henry S, Ashley, David M, Peters, Katherine B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2019
Materias:
Special Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6880304/
https://www.ncbi.nlm.nih.gov/pubmed/31686534
http://dx.doi.org/10.2217/cns-2019-0012
Descripción
Sumario:AIM: Central neurocytoma (CN) is a rare WHO grade II central nervous system (CNS) tumor. This is an update on chemotherapeutic agents used in its treatment. PATIENTS & METHODS: An institutional review board-approved, chart review of patients seen at our institution resulted in a single case treated with chemotherapy and is herein included. We proceeded with a comprehensive literature review. RESULTS: We identified 18 citations, representing 39 cases of adult and pediatric CN treated with chemotherapy. With the addition of our single case, the total number of recurrent CN patients treated with temozolomide (TMZ) is nine. CONCLUSION: There exists marked heterogeneity in chemotherapy used to treat CN. TMZ is incorporated into treatment regimens in the setting of tumor recurrence: its role merits further study.

Ejemplares similares